Non-Hodgkin Lymphoma — Trials

Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,168
Recruiting: 1,127
Ph III recruiting: 115
Growth YoY: +5.7%
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.5%
Trials / 1,000 deaths: 108.5 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,290)

clinicaltrialsPublishedShowing 2,251–2,300 of 2,536 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03836014	Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma(CONFIRM)	active not recruiting	Phase 3	436	Assistance Publique - Hôpitaux de ParisOTHER	1	Dec 6, 2024	clinicaltrials
NCT05203003	Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.(MRD-CONFIRM)	recruiting